Compare BBD & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBD | WST |
|---|---|---|
| Founded | 1943 | 1923 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3B | 17.9B |
| IPO Year | N/A | 2004 |
| Metric | BBD | WST |
|---|---|---|
| Price | $3.62 | $239.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $319.43 |
| AVG Volume (30 Days) | ★ 42.5M | 699.1K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 4.92% | 0.37% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 6.79 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $71.06 | $6.73 |
| Revenue Next Year | $7.82 | $6.07 |
| P/E Ratio | ★ $9.20 | $34.72 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $1.98 | $187.43 |
| 52 Week High | $4.29 | $322.34 |
| Indicator | BBD | WST |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 46.71 |
| Support Level | $3.28 | $238.31 |
| Resistance Level | $3.75 | $251.73 |
| Average True Range (ATR) | 0.11 | 6.35 |
| MACD | -0.05 | -0.77 |
| Stochastic Oscillator | 14.59 | 41.31 |
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.